Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Titel:
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Auteur:
Ascierto, Paolo A Del Vecchio, Michele Robert, Caroline Mackiewicz, Andrzej Chiarion-Sileni, Vanna Arance, Ana Lebbé, Céleste Bastholt, Lars Hamid, Omid Rutkowski, Piotr McNeil, Catriona Garbe, Claus Loquai, Carmen Dreno, Brigitte Thomas, Luc Grob, Jean-Jacques Liszkay, Gabriella Nyakas, Marta Gutzmer, Ralf Pikiel, Joanna Grange, Florent Hoeller, Christoph Ferraresi, Virginia Smylie, Michael Schadendorf, Dirk Mortier, Laurent Svane, Inge Marie Hennicken, Delphine Qureshi, Anila Maio, Michele